Human leukocyte antigen (HLA) class I molecules present a variety of posttranslationally modified epitopes at the cell surface, although the consequences of such presentation remain largely unclear. Phosphorylation plays a critical cellular role, and deregulation in phosphate metabolism is associated with disease, including autoimmunity and tumor immunity. We have solved the high-resolution structures of 3 HLA A2-restricted phosphopeptides associated with tumor immunity and compared them with the structures of their nonphosphorylated counterparts. Phosphorylation of the epitope was observed to affect the structure and mobility of the bound epitope. In addition, the phosphoamino acid stabilized the HLA peptide complex in an epitope-specific manner and was observed to exhibit discrete flexibility within the antigenbinding cleft. Collectively, our data suggest that phosphorylation generates neoepitopes that represent demanding targets for T-cell receptor ligation. These findings provide insights into the mode of phosphopeptide presentation by HLA as well as providing a platform for the rational design of a generation of posttranslationally modified tumor vaccines.
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antigen presentation ͉ HLA ͉ phosphopeptide ͉ T cells ͉ X-ray crystallography P hosphorylation plays a critical role in cellular signaling, and changes in phosphate metabolism are associated with virtually all disease states. The immune system has evolved to survey changes in phosphorylation through the action of both innate and adaptive effector pathways that include specific recognition of phosphoantigens. For example, Toll-like receptor (TLR) 4 and TLR9 perceive various forms of phosphoantigens (1, 2) . Moreover, a subset of ␥␦ T cells recognizes pyrophosphomonoesters that are found in various microbial pathogens (3) . Natural killer (NK) cell recognition of phosphoantigens has also revealed that phosphorylation of human leukocyte antigen (HLA) Cw4-bound peptide antigens reduced inhibitory signals mediated via killer Ig receptors and led to enhanced NK cell cytolysis (4) . Phosphoantigens are also recognized by the adaptive immune system. Recognition of phosphoantigens by antibodies is very well documented (5), and phosphorylated autoantigens are implicated in human autoimmune disorders, such as primary Sjögren's syndrome and lupus (6, 7) . Phosphoantigen surveillance by T cells has been observed in major histocompatibility complex (MHC) class I-and class II-restricted antigen presentation (8) (9) (10) . In addition, HLA A2-restricted tumorspecific phosphopeptides are immunogenic, and cytotoxic T lymphocytes (CTLs) that distinguish between phosphorylated and native peptides can be generated in HLA A2 transgenic mice (9) .
The exquisite sensitivity of CTLs toward subtle changes in peptides presented on the cell surface allows discrimination of infected cells or cells undergoing malignant transformation.
Cancer immunotherapy has focused on the identification of tumor-associated antigens that are expressed exclusively by cancer cells. These antigens fall into 3 broad classes: (i) cancer antigens, such as testis and other embryonic or developmental antigens that are not normally expressed in adult tissues but are expressed in a broad range of tumors (11); (ii) neoantigens generated by mutation in key regulator molecules, such as p53 (12) or aberrant posttranslational modification of proteins (13) ; and (iii) viral antigens associated with cancer, such as EpsteinBarr virus antigens (14) . Many of these antigens are not expressed on the surface of tumor cells, and therefore are not directly accessible to antibodies. Thus, because of the ability of CTLs to survey intracellular protein expression, vaccines that are capable of eliciting such responses represent an attractive option for cancer immunotherapy.
To study the intrinsic link between the deregulated signaling cascade present in many cancers and the ability of antigen processing to alert CTLs to such molecular events, we have investigated the structural and biophysical properties and structures of 3 HLA A2 phosphopeptide complexes derived from cell division cycle (CDC) 25b, ␤-catenin, and insulin receptor substrate (IRS) 2 and have compared them with the structures of their nonphosphorylated counterparts. The presentation of HLA class I-restricted phosphorylated epitopes and the implications for altered self are discussed.
Results and Discussion
Structures of HLA A2 Bound to Phospho-and Native-Peptide Epitopes.
To gain insight into the mode of phosphopeptide presentation, HLA A2 was expressed and refolded in the presence of 3 phosphopeptides. Two of these peptides, a nonamer and decamer, were phosphorylated at the P4 position IRS2 1097 RVApSP TSGV 1105 , ␤-catenin 30 YLDpSGIHSGA 39 , whereas the other nonamer was phosphorylated at the P5 position CDC25b residues 38-46 38 GLLGpSPVRA 46 . These phosphoserine-containing peptides were chosen based on their natural antigen presentation on multiple HLA A2 ϩ tumor cell lines and their immunogenicity in HLA A2 transgenic mice (9).
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The 3 HLA A2 epitopes were subsequently crystallized, and their respective structures were solved and refined to a resolution of 1.8 Å or better (Table 1 ). In addition, to gain insight into how the incorporation of the phospho-moiety influenced the pHLA A2 structure, we determined the structures of the nonphosphorylated counterparts of these peptides bound to HLA A2 to a resolution of 1.93 Å or better (Table 1) . With the exception of the HLA A2 YLDSGIHSGA , in which the central region of the epitope demonstrated high mobility (see below), the mode of binding of the peptides was unambiguous (Fig. 1) .
All 6 pHLA A2 structures determined were crystallized under the same conditions, in the same space group and unit cell dimensions (Table 1 ). In addition, an alignment of the antigenbinding cleft (residues 1-185) of HLA A2 indicated no significant structural rearrangement in the corresponding phosphoand nonphospho-structures (rmsd: CDC25b/CDC25b-phospho, HLA A2 ϭ 0.079 Å, peptide ϭ 0.27 Å; IRS2/IRS2-phospho, HLA A2 ϭ 0.13 Å, peptide ϭ 0.09 Å; ␤-catenin/␤-cateninphospho, HLA A2 ϭ 0.11 Å, peptide ϭ 0.45 Å). In all cases, the phosphate group is prominently surface-exposed and contributes to increased electronegativity at the candidate T-cell receptor (TCR) binding site ( Figs. 2 and 3 ).
CDC25b. The CDC25b peptide (GLLGSPVRA) bound to HLA A2 in a linear and extended manner with a central bulge around the P4-P5 position ( Fig. 1 A) . P2-Leu and P9-Ala are the main anchor residues, whereas P3-Leu also pointed down toward the antigen-binding cleft and contributes to peptide binding. P5-Ser and P8-Arg interact via a water-mediated H-bond, and both project upward, comprising potential TCR contact sites, with P5-Ser leaning toward the ␣1-helix, and forming van der Waals interactions with Ala 69 of HLA A2 (Fig. 2 A) . There are no conformational changes in the HLA A2 heavy chain associated with the accommodation of the phospho-moiety in the HLA A2
GLLGpSPVRA complex (Fig. 1D) . However, the peptide undergoes local conformational changes around the site of phosphorylation at P5 to avoid steric clashes with Ala 69 and Thr 73 of the HLA A2 heavy chain ( Fig. 2 B and C) . This results in the peptide pushing away from the ␣1-helix toward center of the antigenbinding cleft, resulting in a shift of 2 Å in the C␣ position between P5 and P5-phosphoSer and also a change in the conformation of P3-Leu. Moreover, the phosphate group is observed in 2 discrete conformations ( Fig. 2B) , indicative of discrete mobility in this moiety [ Table S1 ]. One conformer forms a salt bridge with P8-Arg, and both conformers interact with the peptide backbone through a water-mediated H-bond to P6-Pro, which appear to be the only interactions the phosphate head group makes ( Fig. 2 A and B) . In this instance, these pHLA complexes define a case of altered self in which the peptide antigen demonstrates significantly altered conformation. These data demonstrate the alteration of a self-pHLA by a posttranslational modification.
IRS2. The IRS2 peptide (RVASPTSGV) also bound to HLA A2 in an extended manner with P2-Val and P9-Val as main anchor residues (Fig. 1B) . In addition, P3-Ala and P6-Thr point downward into the antigen-binding cleft. P1-Arg, P4-Ser, P5-Pro, and P7-Ser are solvent-exposed and potential TCR contact sites, although P4-Ser is not involved in any significant interactions. The phosphorylated IRS2 peptide is accommodated within the HLA A2 binding cleft with little change when compared with the nonphosphorylated counterpart (Fig. 1E ). The differences in the phosphorylated and nonphosphorylated complexes reside predominantly in the addition of an electronegative charge and small changes in the conformation of Lys 66 and Arg 65 (Fig. 2  D-F) . As observed for the CDC25b pHLA complex, the phosphate group at P4 of the IRS2 peptide was observed in 2 conformations, again reflecting flexibility in the phosphomoiety. One conformer interacts with Lys 66 on the ␣1-helix and with Gln 155 on the ␣2-helix through a water-mediated H-bond ( Table S1 ). The second conformer interacts with the Lys 66 and Arg 65 of HLA A2. Thus, the phospho-moiety forms stabilizing contacts with the antigen-binding cleft without disrupting the peptide conformation. A recent structural study of phosphopeptide/HLA A2 complexes suggested a common binding motif for the P4-phosphoSer moiety of peptides, with a positively charged N-terminal residue (15) . The binding mode of the phosphorylated IRS2 peptide only partly follows this motif, however, because the salt bridge to P1-Arg is absent in the HLA A2
RVApSPTSGV complex. This can be attributed to the extended binding geometry of P5-Pro and P6-Thr, which prevents the movement of P4-Ser toward P1 into the position observed by Mohammed et al. (15) . Instead, P1-Arg and Lys 66 adopt side-chain conformations that place the center of the positively charged region somewhat closer to the phosphate moiety. . Gray indicates ␣-chain, with putative TCR contact residues in purple, based on the structure of the A6/HLA A2-Tax complex structure (25) . The arrows indicate the peptide phosphorylation sites. The negatively charged phosphate groups are located within the area of a typical TCR footprint and are likely to dominate TCR discrimination. Electrostatic potentials (blue, positive; red, negative) were calculated with APBS (22) . The phosphoserine residues were assumed to carry 2 negative charges.
␤-Catenin. The native form of this peptide (YLDSGIHSGA) demonstrates marked flexibility in complex with HLA A2, with no electron density observed for positions 5 and 6 (Fig. 1C) . In addition, P3-Asp, P4-Ser, and P7-His exhibit flexibility. The mobility of the central region of the ␤-catenin peptide is not attributable to poor crystallographic data, because the electron density surrounding this region is excellent and, moreover, the structure is at very high resolution (1.65 Å) and well refined [R free ϭ 19.95%]. There is also a degree of mobility of the residues in the floor of the antigen-binding cleft (e.g., Tyr 99, Arg 97) as a result of the peptide flexibility (data not shown). Although the peptide is highly flexible, the primary anchor (P2-Leu and P10-Ala) residues are well defined. The mobility of the nonphosphorylated pHLA is markedly reduced in the phosphorylated pHLA structure, and the entire epitope is clearly visible (Fig. 1F) . Consistent with the other 2 phosphorylated complexes, the phosphate moiety is observed in 2 different conformers, which indicates a general theme of a mobile phosphate group (Fig. 2 G-I) . In the HLA A2 YLDpSGIHSGA complex, P2-Leu and P10-Ala represent the primary anchor residues, with P3-Asp and P6-Ile also projecting downward toward the antigen-binding cleft. The stabilization of the flexible nature of this peptide by phosphorylation can be attributed to stabilizing intrapeptide interactions as well as to interactions with Arg 65 and Lys 66 of HLA A2. In one conformer, the phosphate group interacts with P7-His and Arg 65 and it appears that the P7-His is ''pulled in'' toward the phospho-moiety compared with the nonphosphorylated complex. There is also a water-mediated H-bond between the phosphate group and P1-Tyr (Fig. 2 G and H) .
Overall, the 6 structures have revealed a clear alteration of self when phosphorylated peptides are captured and presented to T cells-not merely via the incorporation of the phosphate moiety that alters the biophysical characteristics of the ligand but in changes in peptide conformation and HLA A2 residues known to influence TCR engagement (16) . The phosphate moiety was observed in multiple conformations, suggesting that this moiety can adopt discrete conformations, thereby potentially representing a ''moving target'' for TCR engagement. In each case, the phosphate sits centrally in the antigen-binding cleft as a prominent electronegative target for T-cell ligation (Fig. 3) . Also shown in Fig. 3 is the putative TCR docking site on the surface of the pHLA complex, which indicates that the phosphate would be highly accessible for interaction with CDR regions of the bound TCR.
Influence of Phosphate Group on Stability and Binding to HLA A2. To determine if the interactions between the phosphate group and HLA A2 residues have an impact on binding and thermostability of the pHLA A2 complexes, thermal denaturation curves and HLA A2 binding studies were undertaken. Good correlation between thermal melt curves incorporating CD measurements of complex structure and competitive binding assays were observed for all 3 peptide sets (Fig. 4) . The ␤-catenin and CDC25b complex stability and HLA A2 binding were essentially unaffected by the phosphorylation of P4-Ser and P5-Ser of the respective peptides. In contrast, the phosphorylation of P4-Ser in the IRS2 peptide resulted in enhanced complex thermostability (increase of Ϸ6°C in T m ) and improved HLA A2 binding (6.3-fold increase in IC 50 ). Thus, phosphorylation can increase the stability of the HLA A2 complex in an epitope-dependent manner.
HLA A2 Protects the Phosphate Moiety from Phosphatases. One issue that surrounds the presence of phosphoserine within the HLA A2 binding cleft is the general labile nature of the phosphate modification. We therefore undertook a series of experiments to determine if the HLA A2 antigen-binding cleft afforded protection to the peptide from phosphatase activity. The kinetics of peptide dephosphorylation were assessed by mass spectrometric analysis of phosphatase-treated samples at different time points. Consistent with the structural studies that showed the phosphate participated in a number of interactions with HLA A2 (Table  S1) , substantial protection from phosphatase activity was observed when the phosphopeptides were bound to HLA A2 compared with the peptide in free solution (Fig. 4 C, F, and I) .
Conclusions
Our structures of HLA A2 complexed to both native and phosphorylated versions of peptide epitopes provide a unique opportunity to visualize the impact of phosphorylation on the bound conformation of the peptide ligand and HLA A2. In particular, conformational adjustments to some HLA A2 residues, peptide conformation, and peptide mobility were observed in an epitope-dependent manner (Fig. 1) . This distinguishes our study from earlier studies (15) in which only the phosphorylated version of the phosphopeptide epitopes was studied. Moreover, our study focuses on epitopes that are phosphorylated at the P4 as well as P5 positions. Incorporation of the phosphate moiety dramatically alters the electrostatic footprint of the pHLA complex, which, coupled to the mobility of the phosphate head group, is predicted to have a profound influence on T-cell recognition.
For the IRS2 epitope, phosphorylation enhanced HLA A2 binding and thermostability, although phosphorylationdependent stabilization of the pHLA A2 was not a general theme. In the ␤-catenin epitope, phosphorylation ordered the conformation of the peptide via the introduction of electrostatic constraints. In all cases, binding to HLA A2 shielded the phosphoserine residue from dephosphorylation by phosphatases, suggesting that once formed, the phosphopeptide complexes are stable. Thus, not only are phosphopeptides transported into the endoplasmic reticulum actively (10) , but on assembly with HLA, they appear to be protected from phosphatase activity, preserving the epitope for scrutiny by T cells at the cell surface. This is consistent with the ability of these peptides to generate phosphopeptide-specific CTLs (9) and the detection of both tumor-specific and self-phosphopeptides in the HLA A2 immunopeptidome (9) . This also suggests that phosphopeptides will be present in the thymus during T-cell ontogeny, shaping the T-cell repertoire and selecting phosphopeptide-specific T cells. Thus, phosphopeptides represent a class of potential vaccine candidates. Their presence on the surface of antigen-presenting cells not only directly reflects the altered signaling events occurring in the transformed cell but generates an altered self-pHLA landscape providing the cytotoxic T-cell effector arm of the immune system an opportunity to remove malignant cells from the host. Clearly, other disease states that have an impact on phosphorylation and related signaling events will also potentially yield distinctive pHLA landscapes that can be discerned by surveying T lymphocytes.
Materials and Methods
Peptides. All peptides were synthesized and purified to Ͼ85% at the Bio21 Peptide synthesis facility. Peptide stocks were prepared and dissolved in DMSO to a final concentration of 10 -100 mg/mL. Expression, Purification, Crystallization, and Structure Determination. Truncated HLA A*0201 class I heavy chain, encompassing residues 1-2745, was expressed as inclusion bodies using the BL21 strain of Escherichia coli as described previously (17) .
Crystals of all pHLA complexes were grown by the hanging drop vapor diffusion method at 20°C using similar precipitant solutions with 2-4 mM MgCl 2, 2-4 mM CdCl2, 0.1 M Hepes (pH 7.4), 100 -200 mM NaCl, and 12-13% PEG3350 (vol/vol). For the IRS2 nonphospho-complex, CoCl 2 was used instead of MgCl 2. Streak-seeding was required to nucleate crystals of both CDC complexes. Crystals appeared after 12-48 h and grew to maximal size in 7-14 days. Crystals were flash-cooled to 100 K before data collection using 20% glycerol (vol/vol). X-ray diffraction experiments were performed using a Rikagu RU-3HBR rotating anode generator with helium-purged OSMIC focusing mirrors coupled to an R-AXIS IV ϩϩ detector (Rikagu). All crystals belong to space group P2 12121, with very similar unit cell dimensions. For a full summary of the data collection statistics, refer to Table 1 .
The structures were solved by molecular replacement using the program Phaser (18) . A modified protomer of a previously solved HLA A2 structure with the peptide residues removed was used as the search probe. Refinement was monitored by the R free value (5% of the data), using the same set of reflections for all data sets. Rigid body refinement and restrained refinement were performed using the program Refmac (19). This was followed by simulated annealing and individual B-factor and total least squares (TLS) refinement in Phenix (20) . Model building was performed using the program Coot (21) . Water molecules and peptides were built into unambiguous electron density during the refinement process. Cd and Co ions were modeled into strong spherical peaks ( Ͼ 8) of the 2Fo-Fc maps, and their occupancies were adjusted manually to fit the maps. Figures were generated with Pymol (DeLano Scientific LLC) and APBS (22) . For the calculation of the unbiased 2Fo-Fc maps shown in Fig. 1 , a single round of simulated annealing and B factor-and TLS refinement was performed with the peptides removed from the models.
CD. CD spectra were measured on a Jasco 815 spectropolarimeter using a thermostatically controlled cuvette at temperatures between 30 and 90°C. Far-UV spectra were collected and analyzed as described (17) .
Competitive HLA A2 Binding Assay. Cells were treated with ice-cold citric acid for 90 s before the binding assay to remove HLA-bound peptides. The competition-based peptide binding assay was performed according to van der Burg et al. (23) . Briefly, 25 L of competitor peptide (different end concentrations) was mixed with 25 L of fluorescence-labeled reference peptide [GILGK(FITC)VFTL, end concentration ϭ 150 ng/mL] in a 96-well V-bottom plate. One hundred microliters of mild acid-treated JY cells (5 ϫ 10 4 /well) was added to the wells and incubated at 4°C for 24 h. Cells were washed with PBS containing 1% BSA; 10 L of propidium iodide (1 mg/ml solution) was added, and the mean fluorescence (MF) was then measured by FACScan (Becton Dickinson). Percentage inhibition of fluorescent peptide binding was calculated using the following formula:
͑1 Ϫ ͑MF referenceϩcompetitor peptide Ϫ MF no reference peptide ͒/ ͑MF reference peptide Ϫ MF no reference peptide ͒͒ ϫ 100% 
